311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine

Neurology

Volumn 48, Issue 3 SUPPL. 3, 1997, Pages

  Zagami, A S ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SOMNOLENCE;

EID: 0030891432     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.3_suppl_3.25s     Document Type: Article

References (7)

1. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90. Headache 1994;34:394-399.
2. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996;36(suppl 2):4-7.
3. 1D receptor agonist in the acute oral treatment of migraine: a double blind, placebo controlled, dose range finding study. Neurology 1996;46: 522-526.
4. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
5. 1B/1D receptor agonists. Neurology 1997;48(suppl 3):S21-S24.
6. Geraud GEA. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Eur Neurol 1996; 36(suppl 2):24-27.
7. Earl NL. Clinical safety of 311C90: aggregated data from patients and volunteers to date. Eur Neurol 1996;36(suppl 2):8-12.